Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes-Reference-Cited by-同舟云学术

Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes

Published:2017-02-16 Issue:4 Volume:281 Page:365-382
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Landgren O.¹,Iskander K.²

Affiliation:

1. Myeloma Service; Division of Hematology Oncology; Department of Medicine; Memorial Sloan-Kettering Cancer Center; New York NY USA

2. Department of Clinical Development; Amgen; Thousand Oaks CA USA

Funder

Core

Amgen

Publisher

Wiley

Subject

Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/joim.12590/fullpdf

Reference76 articles.

1. Multiple myeloma;Palumbo;N Engl J Med,2011

2. Improved long-term survival in multiple myeloma up to the age of 80 years;Kristinsson;Leukemia,2014

3. United States Food and Drug Administration Hematology/Oncology (Cancer) Approvals & Safety Notifications http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm

4. Association of response endpoints with survival outcomes in multiple myeloma;Lonial;Leukemia,2014

5. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma;Korde;JAMA Oncol,2015

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review;Frontiers in Oncology;2024-01-25

2. Biomedical Approach of Nanotechnology and Biological Risks: A Mini-Review;International Journal of Molecular Sciences;2023-11-24

3. Flow Cytometry in Diagnosis, Prognostication, and Monitoring of Multiple Myeloma and Related Disorders;Clinics in Laboratory Medicine;2023-09

4. CircRNAs in diagnosis, prognosis, and clinicopathological features of multiple myeloma; a systematic review and meta-analysis;Cancer Cell International;2023-08-26

5. Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma;Haematologica;2023-08-24